Meeting
2022 ASCO Annual Meeting
Evaluation of somatic and germline variants in patients with small bowel adenocarcinoma reveals clinically actionable targets.
Authors
Deng Wei
Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
Deng Wei , Si Liu , Xiaomo Li , Tonghui Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Small Bowel Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4159)
DOI
10.1200/JCO.2022.40.16_suppl.4159
Abstract #
4159
Poster Bd #
144
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
First Author: Rachna T. Shroff
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2022 ASCO Annual Meeting
Molecular typing and clinical characteristics of synchronous multiple primary colorectal cancer.
First Author: Jun Huang
Poster
2020 Gastrointestinal Cancers Symposium
Clinical utility of targeted next generation sequencing (NGS) to predict response to neoadjuvant therapy (NT) in rectal cancer (RC).
First Author: Kristen Carroll